Fennec Pharmaceuticals shares were down after the company reported fourth-quarter results. The stock was recently down 10% to $6.20 and is down about 2% this year. Revenue declined to $7.93 ...

Early Repayment of $13 Million of the Company’s Approximately $32 Million Outstanding Convertible Debt Facility: In December 2024, Fennec announced the early partial repayment of a significant ...

FENNEC PHARMACEUTICALS ($FENC) posted quarterly earnings results on Monday, March 10th. The company reported earnings of -$0.06 per share, missing estimates of $0.17 ...

Felix Ampomah; Analyst; Stephens, Inc. Good morning ladies and gentlemen, and welcome to Fennec Pharmaceuticals fourth quarter and full year 2024 earnings and corporate update conference call.

A number of research analysts recently issued reports on FENC shares. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.

(RTTNews) - Fennec Pharmaceuticals Inc (FENC) released Loss for fourth quarter that decreased from last year and beat the Street estimates. The company's earnings totaled -$1.62 million ...

Fennec Pharmaceuticals Inc (FENC) reports a 40% revenue increase and successful PEDMARK launches in Europe, while navigating competitive challenges and operational expenses.